Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -2.78% 87.50 85.00 90.00 90.00 87.50 90.00 15,829 16:11:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.7 -9.1 -8.0 - 103

Shield Therapeutics Share Discussion Threads

Showing 5676 to 5699 of 6225 messages
Chat Pages: Latest  237  236  235  234  233  232  231  230  229  228  227  226  Older
DateSubjectAuthorDiscuss
27/4/2020
10:36
peachie, new appointment should speed matters up but I doubt any news until after lock down has ended. Stay safe - Stay patient, I have stayed patient since the risky days of 30p’s We are only where we were the day before FDA broad label approval announcement last summer..so a way to go here
ny boy
27/4/2020
10:19
Imagine how quick this is going rise on good news. And that could be pretty soon hopefully.
peachie 74
26/4/2020
12:43
https://bnf.nice.org.uk/drug/iron-sucrose.html Shows IV irons many complications. Especially of note that cardiopulmonary resuscitation equipment needed.
peachie 74
25/4/2020
09:05
The following lines from above sum it up very well ! “The London-based company said the FDA had approved its lead product Ferracru/Accrufer (ferric maltol) in a market that could be worth $1 billion annually. The FDA approved the product for treatment of iron deficiency with or without anaemia, allowing use for as long as necessary to restore iron levels. This allows for long-term use in patients with chronic disease – there are between 8 million and 9 million patients in the US suffering from iron deficiency anaemia and management estimates two to three times this number require treatment for iron deficiency.”
peachie 74
25/4/2020
09:03
I think we need a reminder just how big this could be ..... Richard StainesRichard StainesJuly 26, 2019 Shares in Shield Therapeutics were soaring this morning after the FDA granted a broader than expected label for its iron deficiency drug. The London-based company said the FDA had approved its lead product Ferracru/Accrufer (ferric maltol) in a market that could be worth $1 billion annually. The FDA approved the product for treatment of iron deficiency with or without anaemia, allowing use for as long as necessary to restore iron levels. This allows for long-term use in patients with chronic disease – there are between 8 million and 9 million patients in the US suffering from iron deficiency anaemia and management estimates two to three times this number require treatment for iron deficiency. Shield said it is already in discussions with commercial partners to market the drug in the US and will provide an update in due course. The company noted that salt-based iron therapies can cause a range of mild-to-severe gastrointestinal tract adverse events, including nausea, bloating, and constipation. These can lead to poor tolerability, reduced patient compliance and treatment failure. As Ferracru/Accrufer is not an iron salt, iron can be absorbed from the ferric maltol molecule and does not routinely cause the same issues. Under the brand name Ferracru the drug is already approved and marketed in the EU and Switzerland for iron deficiency in adults. Mark Brewer, an analyst at finnCap, said: “The FDA granted a broader than expected label, given Feraccru’s tolerability profile and efficacy – the treatment of Iron Deficiency (ID) with or without anaemia – with the label indicating its use for as long as necessary to restore iron levels, implying a chronic therapy. “This at least doubles the potential addressable market for Accrufer. Together with the non-inferiority data vs. IV iron, announced in March, this offers the potential for Accrufer to remove the need for patients to progress to IV therapy.” Dr Daniel Wilkinson, analyst at Edison Investment Research, noted this was the “largest possible label” the FDA could have granted. He said: “This is an upside to our previous assumptions where we had assumed a narrower label and enables a larger commercial opportunity. Shield are in discussion with a number of potential commercial partners in the US who will market Accrufer on its behalf.” Carl Sterritt, CEO of Shield Therapeutics said: “We have been pleased with the levels of interest and engagement shown by third parties in commercialising Accrufer in the USA and we look forward to finalising these discussions and appointing a commercial partner in the world’s most attractive pharmaceutical market, so that more patients with iron deficiency can benefit from treatment with Accrufer at the earliest opportunity.”
peachie 74
24/4/2020
11:02
Just some random reading.... A little example of the size of the market ... Globally, the prevalence of anaemia among pregnant women was estimated as 38ยท2% in 2011.1 In 2015, the prevalence of moderate-to-severe anaemia in pregnancy ranged from 40% to 60% in India.2 More than 60% of anaemia cases are estimated to be due to iron deficiency.3 Nearly 20% of all maternal deaths are attributed directly to anaemia and 20% to indirect causes of anaemia, which include haemorrhage and sepsis.4 Oral iron is the most commonly prescribed therapy for pregnant women with mild-to-moderate anaemia;5,6 how- ever, compliance to oral iron is poor because of gastro- intestinal side-effects.6,7 In several countries, parenteral iron preparations such as iron dextran, iron sucrose, sodium ferric gluconate, and ferric carboxymaltose are recommended as an alternative treatment modality for pregnant women who fail to respond to oral therapy.8,9 In cases of severe anaemia, blood transfusion remains the mainstay treatment.
peachie 74
23/4/2020
16:48
Well those that panic sold the other day doh! Stay safe - stay patient, be very greedy during market meltdowns imo
ny boy
23/4/2020
11:46
GOING UP ONCE AGAIN
frrinvest
23/4/2020
08:01
Come on then Shield. So much promise here. Massive worldwide potential..Lets get going !
peachie 74
22/4/2020
17:44
A good note from Edison. Thank you for bringing it to our attention. I did manage to get more when the price dropped earlier in the morning. With FDA approval of its flagship product, STX has to be one of the cheapest in the market.
frrinvest
22/4/2020
17:08
Edison keep their 294p rating https://www.edisongroup.com/publication/tim-watts-succeeds-carl-sterritt-as-ceo/26655
peachie 74
22/4/2020
16:46
I personally don’t think the little H2H mix up carries any where near enough weight for Carl to leave. I think it’s more to do with large investors pressing for something. Strange they were mentioned in the RNS as well as the BOD. He’s staying on to help integrate Tim which suggests no sour grapes. But perhaps the investors want the US deal pushing harder , or as mentioned they want a bigger bit of involvement from a bigger company. A phase 3 tested product. Safe. FDA BROAD label approved. US deal coming. ASK taking it forward in China, Hong Kong and Taiwan. Looking to address child Fe deficiency. Not far of phase 3 PT20 ( would be very big in itself , look int hyperphosphataemia ) I believe this is still massively undervalued. But DYOR. GLA holders
peachie 74
22/4/2020
13:52
Market doesn’t seem to care Carl’s gone. It’s a shame it turned sour for him but as CEO he carries the can for misleading the market on the H2H. Probably the investors thought his strategy was not working out in Europe. Clearly no movement from Norgine to get prices. They are a specialty Pharma business. This is a mass market drug. Europe needed a complete rethink and likely it would mean getting it back from Norgine.
crankyman
22/4/2020
13:07
78steve you had a chance to buy at 50p recently, don’t be greedy now lol Maybe you have missed the express train to next Station 350p
ny boy
22/4/2020
12:54
Why on earth would that happen ? Why is it possible to you. What reason ? More chance of hitting 150. Of course no crystal ball here , but if that’s you’re entry point Steve it maybe a while Edit. Of course every share has risk. Could find out Feraccru kills over 70s !!!!! 50p here we come. Conversely we could find out some US deal is done for millions or we are being looked at for takeover... 350 here we come
peachie 74
22/4/2020
12:37
Is there another chance this will hit 50p like it did couple months back? Seems possible to me but who knows
78steve
22/4/2020
12:07
We will be blue soon at this rate !
peachie 74
22/4/2020
11:48
Glad his gone probably holding price back, now let's a deal done. But takeover I reckon.
montyhedge
22/4/2020
11:20
I've gone in for 3000 more. still not got em. Not showing yet and ? price
peachie 74
22/4/2020
10:31
For a start chairman bought 75,000 at 178 last year !!!!!!
peachie 74
22/4/2020
10:28
No one has said is imminent. its a possible (optimistic) reason for price rise and CEO leaving. 30 percent anyway, No chance.
peachie 74
22/4/2020
10:04
For those promoting the prospect of an immanent take over bid what would the price be? 30 per cent premium on closing price today? Before or after US deal concluded or instead of?
borromini1
22/4/2020
09:37
Can sell 20,000 at 98 online Edit. And buy 10,000 at 98 !!!! Good old MMs
peachie 74
22/4/2020
09:31
Great paragraph ... Prior to Feraccru (R) /Accrufer(R) , IV iron therapies were the only realistic alternative treatment option for iron deficient patients with or without anaemia intolerant of or unwilling to be treated salt-based oral iron therapies. However, use of such an invasive, costly, inconvenient and complex to administer treatment option, which is associated with potentially life-threatening and spontaneous hypersensitivity reactions, means there remains a clear unmet medical need for these patients to have access to an effective therapy that is well tolerated, convenient and does not require hospital-based administration. Feraccru (R) /Accrufer(R) meets those requirements.
peachie 74
Chat Pages: Latest  237  236  235  234  233  232  231  230  229  228  227  226  Older
ADVFN Advertorial
Your Recent History
LSE
STX
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200712 22:31:39